查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
神經營養性角膜炎的全球市場-成長，未來展望，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1149076

神經營養性角膜炎的全球市場-成長，未來展望，競爭分析(2022年～2030年)

Neurotrophic Keratitis Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

全球神經營養性角膜炎的市場規模在2022年～2030年的預測期間內預計將以5.2％的年複合成長率增長。神經營養性角膜炎的盛行率上升，合適的給付方案，地區醫療機關所提供的支援性法規方案，促進了神經營養性角膜炎市場的成長。

本報告提供全球神經營養性角膜炎市場相關調查分析，提供商務展望，市場動態，市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
    • 報告的目的
    • 對象者
    • 主要的產品
  • 市場區隔
  • 調查手法
    • 階段Ⅰ-2次調查
    • 階段Ⅱ-1次調查
    • 階段Ⅲ-專家的審查
    • 假設
    • 所採用的方法

第2章 摘要整理

  • 市場概述:全球神經營養性角膜炎市場
  • 全球神經營養性角膜炎市場(100萬美元)(2021年):不同治療
  • 全球神經營養性角膜炎市場(100萬美元)(2021年):各地區
  • COVID-19影響
  • 富有魅力的投資提案(2021年):各地區
  • 競爭分析
    • 主要的神經營養性角膜炎市場供應商的市場定位
    • 神經營養性角膜炎市場供應商採用的策略
    • 主要的產業策略

第3章 神經營養性角膜炎市場:商務展望和市場動態

  • 簡介
  • 全球神經營養性角膜炎的市場金額(100萬美元)(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析
  • 波特的五力分析
    • 供應商的力量
    • 買主的力量
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭企業間的敵對關係
  • PESTEL分析
    • 政治
    • 經濟
    • 技術性
    • 法律
    • 社會

第4章 神經營養性角膜炎市場，美金(100萬)(2020年～2030年):不同治療

  • 市場概要
  • 成長和收益分析:2021年和2030年的比較
  • 市場區隔
    • 防腐劑不使用的人工淚液
    • 局部抗生素
    • 眼皮板縫合術
    • 羊膜移植
    • 繃帶隱形眼鏡
    • 重組人神經生長因子

第5章 北美的神經營養性角膜炎市場，美金(100萬)(2020年～2030年)

第6章 英國及歐洲聯盟的神經營養性角膜炎市場，美金(100萬)(2020年～2030年)

第7章 亞太地區的神經營養性角膜炎市場，美金(100萬)(2020年～2030年)

第8章 南美的神經營養性角膜炎市場，美金(100萬)(2020年～2030年)

第9章 中東及非洲的神經營養性角膜炎市場，美金(100萬)(2020年～2030年)

第10章 企業簡介

  • Allergan, Plc.
  • Abbott Laboratories, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • CooperVision
  • Dompe farmaceutici S.p.A.
  • Johnson & Johnson
  • Novartis AG
  • ReGenTree, LLC.
  • Walgreens
Product Code: 138735-08-22

Industry Outlook

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2022 to 2030. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease. Currently RGN-259 developed by ReGenTree, LLC. is in the phase III clinical trial study for the treatment of neurotrophic keratitis.

Recent EMA approval of Oxervate and priority review designation approved by the USFDA will popularize the recombinant human nerve growth factor during the forecast period

Neurotrophic keratitis is a rare degenerative disease which results I loss of corneal sensation and dampens its healing process. The global prevalence rate of neurotrophic keratitis is reported to be 5 per 10,000 individuals. The treatment options adopted for neurotrophic keratitis depends upon the severity and stage of the disease. Artificial tears are prescribed for all the stages due to its ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. Topical antibiotics are majorly prescribed during the stage 2 of the disease for prophylactic treatment of infection. Despite pharmacological treatment and in stage 3 of the disease surgical interventions such as Tarsorraphy and amniotic membrane transplantation is employed to heal corneal ulceration. The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factor for the treatment of neurotrophic keratitis during the forecast period.

Rising prevalence of neurotrophic keratitis and affordable reimbursement scenario drive the market growth in North America

North America is presently responsible for 33% market share and is leading the regional segment for neurotrophic keratitis market. According to American Academy of Ophthalmology (AAO), approximately 65,000 people in the United States are suffering with this rare disease. The chief contributing factors accountable for its dominance in regional market are rising prevalence of neurotrophic keratitis and affordable reimbursement scenario pertaining to the medication used for its treatment. Europe trails North America in regional market with a share of 28.5% primarily due to strategic collaboration between government healthcare agencies and academic research institutes for the development of novel drugs for treating neurotrophic keratitis in Europe. The European Medical Agency (EMA) has designated orphan disease status to neurotrophic keratitis and has designated fast track status for its drug development and sale in the region. Asia Pacific holds 16% market share owing to the increasing incidence rate of neurotrophic keratitis in geriatric population and supportive regulatory scenario provided by regional healthcare agencies.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Neurotrophic Keratitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Neurotrophic Keratitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

  • Preservative-Free Artificial Tears
  • Topical Antibiotics
  • Tarsorraphy
  • Amniotic Membrane Transplantation
  • Bandage Contact Lenses
  • Recombinant Human Nerve Growth Factor

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Neurotrophic Keratitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Neurotrophic Keratitis market?
  • Which is the largest regional market for Neurotrophic Keratitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Neurotrophic Keratitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Neurotrophic Keratitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Neurotrophic Keratitis Market
  • 2.2. Global Neurotrophic Keratitis Market, By Treatment, 2021 (US$ Million)
  • 2.3. Global Neurotrophic Keratitis Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Neurotrophic Keratitis Market Vendors
    • 2.6.2. Strategies Adopted by Neurotrophic Keratitis Market Vendors
    • 2.6.3. Key Industry Strategies

3. Neurotrophic Keratitis Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Neurotrophic Keratitis Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Preservative-Free Artificial Tears
    • 4.3.2. Topical Antibiotics
    • 4.3.3. Tarsorraphy
    • 4.3.4. Amniotic Membrane Transplantation
    • 4.3.5. Bandage Contact Lenses
    • 4.3.6. Recombinant Human Nerve Growth Factor

5. North America Neurotrophic Keratitis Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)
  • 5.3.Neurotrophic Keratitis Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Neurotrophic Keratitis Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)
  • 6.3.Neurotrophic Keratitis Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Neurotrophic Keratitis Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)
  • 7.3.Neurotrophic Keratitis Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Neurotrophic Keratitis Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)
  • 8.3.Neurotrophic Keratitis Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Neurotrophic Keratitis Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Neurotrophic Keratitis Market: By Treatment, 2020-2030, USD (Million)
  • 9.3.Neurotrophic Keratitis Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Allergan, Plc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Abbott Laboratories, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Bausch & Lomb Incorporated
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Bayer AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. CooperVision
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Dompe farmaceutici S.p.A.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Johnson & Johnson
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Novartis AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. ReGenTree, LLC.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Walgreens
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)
  • TABLE 2 North America Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)
  • TABLE 5 Latin America Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Neurotrophic Keratitis Market By Treatment, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Neurotrophic Keratitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Neurotrophic Keratitis Market: Quality Assurance
  • FIG. 5 Global Neurotrophic Keratitis Market, By Treatment, 2021
  • FIG. 6 Global Neurotrophic Keratitis Market, By Geography, 2021
  • FIG. 7 Global Neurotrophic Keratitis Market, By Treatment, 2021 Vs 2030, %
  • FIG. 8 U.S. Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 15 France Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 17 China Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 19 India Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Neurotrophic Keratitis Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Neurotrophic Keratitis Market (US$ Million), 2020 - 2030